Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.62), $0.18 better than the analyst estimate of ($2.80). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $12.85 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.